{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:17:34Z","timestamp":1791605854706,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>TG103, a glucagon-like peptide-1 analog, is being investigated as an option for weight management. We aimed to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese without diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this randomized, double-blind, placebo-controlled, multiple-dose phase 1b study, participants aged 18\u201375\u00a0years with a body-mass index (BMI)\u2009\u2265\u200926.0\u00a0kg\/m<jats:sup>2<\/jats:sup> and body weight\u2009\u2265\u200960\u00a0kg were enrolled from three centers in China. The study included three cohorts, and in each cohort, eligible participants were randomly assigned (3:1) to one of three once-weekly subcutaneous TG103 groups (15.0, 22.5 and 30.0\u00a0mg) or matched placebo, without lifestyle interventions. In each cohort, the doses of TG103 were escalated in 1-week intervals to the desired dose over 1 to 4\u00a0weeks. Then participants were treated at the target dose until week 12 and then followed up for 2\u00a0weeks. The primary endpoint was safety and tolerability assessed by the incidence and severity of adverse events (AEs) from baseline to the end of the follow-up period. Secondary endpoints included pharmacokinetic and pharmacodynamic profiles of TG103 and the occurrence of anti-drug antibodies to TG103.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 147 participants were screened, and 48 participants were randomly assigned to TG103 (15.0, 22.5 and 30.0\u00a0mg groups, <jats:italic>n<\/jats:italic>\u2009=\u200912 per group) or placebo (<jats:italic>n<\/jats:italic>\u2009=\u200912). The mean (standard deviation, SD) age of the participants was 33.9 (10.0) years; the mean bodyweight was 81.65 (10.50) kg, and the mean BMI was 29.8 (2.5) kg\/m<jats:sup>2<\/jats:sup>. A total of 466 AEs occurred in 45 of the 48 participants, with 35 (97.2%) in the TG103 group and 10 (83.3%) in the pooled placebo group. Most AEs were grade 1 or 2 in severity, and there were no serious adverse events (SAEs), AEs leading to death, or AEs leading to discontinuation of treatment. The steady-state exposure of TG103 increased with increasing dose and was proportional to C<jats:sub>max,ss<\/jats:sub>, AUC<jats:sub>ss<\/jats:sub>, AUC<jats:sub>0-t<\/jats:sub> and AUC<jats:sub>0-inf<\/jats:sub>. The mean values of C<jats:sub>max,ss<\/jats:sub> ranged from 951 to 1690\u00a0ng\/mL, AUC<jats:sub>0-t<\/jats:sub> ranged from 150 to 321\u00a0\u03bcg*h\/mL, and AUC<jats:sub>0-inf<\/jats:sub> ranged from 159 to 340\u00a0\u03bcg*h\/mL. TG103 had a half-life of 110\u2013116\u00a0h, with a median T<jats:sub>max<\/jats:sub> of 36\u201348\u00a0h. After treatment for 12\u00a0weeks, the mean (SD) values of weight loss from baseline in the TG103 15.0\u00a0mg, 22.5\u00a0mg and 30.0\u00a0mg groups were 5.65 (3.30) kg, 5.35 (3.39) kg and 5.13 (2.56) kg, respectively, and that in the placebo group was 1.37 (2.13) kg. The least square mean percent weight loss from baseline to D85 in all the TG103 groups was more than 5% with <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 for all comparisons with placebo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this trial, all three doses of once-weekly TG103 were well tolerated with an acceptable safety profile. TG103 demonstrated preliminary 12-week body weight loss without lifestyle interventions, thus showing great potential for the treatment of overweight and obesity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov, NCT04855292. Registered on April 22, 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-024-03394-z","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T23:02:24Z","timestamp":1716937344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study"],"prefix":"10.1186","volume":"22","author":[{"given":"Diaozhu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huisheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiwen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingtong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"3394_CR1","unstructured":"World Health Organization. Overweight and obesity. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 10 May, 2023."},{"key":"3394_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S2213-8587(22)00033-X","volume":"10","author":"M Kivim\u00e4ki","year":"2022","unstructured":"Kivim\u00e4ki M, Strandberg T, Pentti J, Nyberg ST, Frank P, Jokela M, et al. Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022;10:253\u201363.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3394_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007292","volume":"14","author":"L Mu","year":"2021","unstructured":"Mu L, Liu JM, Zhou GH, Wu CQ, Chen BW, Lu Y, et al. Obesity prevalence and risks among chinese adults: findings from the China PEACE million persons project, 2014\u20132018. Circ Cardiovasc Qual Outcomes. 2021;14: e007292.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"3394_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurpub\/cku170","volume":"25","author":"ML Specchia","year":"2015","unstructured":"Specchia ML, Veneziano MA, Cadeddu C, Ferriero AM, Mancuso A, Ianuale C, et al. Economic impact of adult obesity on health systems: a systematic review. Eur J Public Health. 2015;25:255\u201362.","journal-title":"Eur J Public Health"},{"key":"3394_CR5","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/2327-6924.12510","volume":"29","author":"SM Fruh","year":"2017","unstructured":"Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract. 2017;29:S3-14.","journal-title":"J Am Assoc Nurse Pract"},{"key":"3394_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"A Afshin","year":"2017","unstructured":"GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13\u201327.","journal-title":"N Engl J Med"},{"key":"3394_CR7","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, Despr\u00e9s J-P, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143:e984-1010.","journal-title":"Circulation"},{"key":"3394_CR8","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/oby.2009.472","volume":"18","author":"M Stommel","year":"2010","unstructured":"Stommel M, Schoenborn CAJO. Variations in BMI and prevalence of health risks in diverse racial and ethnic populations. Obesity. 2010;18:1821\u20136.","journal-title":"Obesity"},{"key":"3394_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/dom.14270","volume":"23","author":"S Theilade","year":"2021","unstructured":"Theilade S, Christensen MB, Vilsb\u00f8ll T, Knop FK. Obesity, Metabolism: An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. Diabetes Obes Metab. 2021;23:17\u201335.","journal-title":"Diabetes Obes Metab"},{"key":"3394_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1037\/amp0000517","volume":"75","author":"TA Wadden","year":"2020","unstructured":"Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75:235\u201351.","journal-title":"Am Psychol"},{"key":"3394_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201\u201323.","journal-title":"Nat Rev Drug Discov"},{"key":"3394_CR12","doi-asserted-by":"crossref","unstructured":"Albaugh VL, Abumrad NN. Surgical treatment of obesity. F1000Res. 2018;7:617.","DOI":"10.12688\/f1000research.13515.1"},{"key":"3394_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/17512433.2020.1698291","volume":"13","author":"AK Singh","year":"2020","unstructured":"Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol. 2020;13:53\u201364.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3394_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bph.15638","volume":"179","author":"S Trapp","year":"2022","unstructured":"Trapp S, Brierley D. Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment. Br J Pharmacol. 2022;179:557\u201370.","journal-title":"Br J Pharmacol"},{"key":"3394_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.935823","volume":"13","author":"X Gao","year":"2022","unstructured":"Gao X, Hua XL, Wang X, Xu WB, Zhang Y, Shi C, et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13: 935823.","journal-title":"Front Pharmacol"},{"key":"3394_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0140-6736(18)31826-9","volume":"392","author":"AY Kluger","year":"2018","unstructured":"Kluger AY, McCullough PA. Semaglutide and GLP-1 analogues as weight-loss agents. Lancet. 2018;392:615\u20136.","journal-title":"Lancet"},{"key":"3394_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jim-2021-001952","volume":"70","author":"G Singh","year":"2022","unstructured":"Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70:5\u201313.","journal-title":"J Investig Med"},{"key":"3394_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106448","volume":"185","author":"JL Jin","year":"2023","unstructured":"Jin JL, Cui G, Mi N, Wu W, Zhang X, Xiao CY, et al. Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1\/Fc fusion protein after a single ascending dose in Chinese healthy subjects. Eur J Pharm Sci. 2023;185: 106448.","journal-title":"Eur J Pharm Sci"},{"key":"3394_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/dia.2014.0188","volume":"17","author":"F Sun","year":"2015","unstructured":"Sun F, Chai SB, Yu K, Quan XC, Yang ZR, Wu SS, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther. 2015;17:35\u201342.","journal-title":"Diabetes Technol Ther"},{"key":"3394_CR20","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","volume":"397","author":"LB Enebo","year":"2021","unstructured":"Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397:1736\u201348.","journal-title":"Lancet"},{"key":"3394_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327:138\u201350.","journal-title":"JAMA"},{"key":"3394_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"3394_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O'Neil","year":"2018","unstructured":"O\u2019Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637\u201349.","journal-title":"Lancet"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03394-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T23:04:56Z","timestamp":1716937496000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03394-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3394"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03394-z","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was reviewed and approved by the institutional review board or ethics committee of each participating center and was conducted in accordance with the principles of the Declaration of Helsinki. All the participants provided written informed consent before study initiation. Sun Yat-sen Memorial Hospital: 2021-YW-036. Beijing Anzhen Hospital: (2021) Pharmaco ethics approval No.16. Nanjing Drum Tower Hospital: 2021-130-02.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jing Yuan, Ziyan Li, Jinlan Yang, Huanhuan Gao, and Ying Xie are employees of CSPC Pharmaceutical Group Co., Ltd. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}